WO1997034580A1 - Suppository composition of the drug which has gastro-intestinal disturbances or undergoes the decomposition by gastric acid - Google Patents
Suppository composition of the drug which has gastro-intestinal disturbances or undergoes the decomposition by gastric acid Download PDFInfo
- Publication number
- WO1997034580A1 WO1997034580A1 PCT/KR1997/000042 KR9700042W WO9734580A1 WO 1997034580 A1 WO1997034580 A1 WO 1997034580A1 KR 9700042 W KR9700042 W KR 9700042W WO 9734580 A1 WO9734580 A1 WO 9734580A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- suppository composition
- drug
- composition
- gastro
- suppository
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
Abstract
This invention relates to a suppository composition containing a drug which has gastro-intestinal disturbances or undergoes the decomposition by gastric acid, poloxamer and hydrophilic natural polymers. The suppository composition of this invention is characterized in that it has a gelation temperature of 30 to 36 °C, and is a liquid form at room temperature, and readily becomes a gel at body temperature after rectal administration; it has the remarkable gel strength, and is not leaked out the anus; it has the remarkable bioadhesive force, and doesn't climb up to the end of the colon, therefore ensures absorption of the drug without gastro-intestinal disturbances or the decomposition by gastric acid.
Description
THE TITLE OF INVENTION
Suppository composition of the drug which has gastro-intestinal disturbances or undergoes the decomposition by gastric acid
TECHNICAL FIELD
This invention relates to the suppository composition of the drug which has gastro-intestinal disturbances or undergoes the decomposition by gastric acid and more particularly, a suppository composition of the drug which has gastro-intestinal disturbances or undergoes the decomposition by gastric acid, being characterized in that said composition;
- has the gelation temperature of 30 to 36 °C , and is a liquid form at room temperature, and readily becomes a gel at body temperature after rectal administration; - has the remarkable gel strength, and is not leaked out the anus;
- has the remarkable bioadhesive force, and doesn't climb upto the end of the colon, therefore ensures absorption of the drug without gastro- intestinal disturbances or the decomposition by gastric acid.
BACKGROUND ART
The oral drug administration is the commonest method designed to apply the drugs into the human body. However, some drugs irritate the gastro-intestinal tract, thus inducing gastro-intestinal disturbances such as bleeding, vomiting, and indigestion. In addition, some drugs are well decomposed by gastric acid. These may lead to significantly reduced therapeutic efficacy. The drugs which have gastro-intestinal disturbances include aspirin, acetaminophen, ketoprofen, indomethacin, naproxen, Fe compound, ketoconazole, itraconazole, econazole, and cepha-antibiotics, and the drugs which undergo the decomposition by gastric acid include propoxyphene, meperidine, methadone, penthazoic acid, dexamethazone, p-aminobenzoic acid, sulfonamides, p-aminohippuric acid, estrogens,
omeprazole, pancreatine, seratiopeptidase, 1-dopa, a -methyldopa, hydrocortisone, cortisone, aldosterone, progesteron, and insulin.
In an attempt to overcome such shortcomings, much research on aspirin and acetaminophen has focused on their various formulations such as microcapsule and enteric coated dosage forms (Leonards, et al. N. Engl. J. Med., 288, 1 1 10-1113(1973)), but their production process is much complicated with relatively slow duration of onset. Further some iron- containing compounds have been launched in the enteric coated and/or sustained release dosage forms but gastro-intestinal disturbances cannot be completely solved.
Omeprazole has been commercialized in an enteric form so as not to be decomposed by gastric juice (Pilbrant and Cederberg, Scan. J. Gastroenterology, 20(108) 13-120(1985)), but its manufacturing process is also complicated due to double-coating formulation containing alkali substance.
Since insulin, when administered orally, is inactivated in the stomach, the main route of administration is given in injectable form but there remain always some risk associated with such administration route. To overcome the aforementioned defects, various formulations such as iontophoresis (Shim B., Polymer(Korea) , 18(3), 384-390(1994)) or skin permeation using absoφtive enhancer (Watanabe Y., Chem, Pharm Bull, 39(11), 3007-3012(1991)) have been suggested. However, said formulation has raised some problems due to inconvenient administration and low absorption rate (Bliss, "The discovery of Insulin", 1983). Under such circumstances, pancreatin or seratiopeptidase has been given as an enteric coated tablet only.
Meantime, intensive formulation studies for suppository form have been made on acetaminophen or aspirin so as to avoid any gastro- intestinal disturbances when administered orally, as well as on omeprazole to avoid its decomposition by gastric juice. Nevertheless, such suppository form have some disadvantages such as difficulty in
manufacture and handling, disgust feeling on the part of patients during administration, and discomforts.
The inventor et al. have noticed the rectal administration of drugs which have gastro-intestinal disturbances or undergo the decomposition by gastric acid and in order to get over the aforementioned shortcomings associated with said rectal administration, poloxamer as suppository base is under careful consideration since such base is in a liquid phase at low temperature but when temperature goes up, it becomes in a gel phase.
In recent years, considerable interest has focused on some approaches to apply the poloxamer into the human body. For example the U.S. Pat. No. 4,188,373 discloses the adjustment of gelation temperature depending on varied concentrations of poloxamer and the Canadian Pat. No. 1,072,413 also discloses varied gelatin temperatures of bases through mixing with Tetronic and Tergitol , poloxamer derivatives. Several U.S. Pat. Nos. 4,478,822, 4,474,751, 4,474,752 and
4,474,753 also disclose that using poloxamer as a base, various kinds of additive are employed so as to adjust the ion strength and pH as well as to apply it into skin, eye and the body cavity such as rectum and urinary tract. However, the conventional gel composition using said poloxamer has some disadvantages in that when rectal administration is given, due to undesirable conditions of gelation temperature, gel strengh and bioadhesive force, the dosage may be leaked out from the anus, or climb upto the end of the colon. Thus the drug of that dosage form may not be absorbed, or that absorbed at colon undergo the hepatic first-pass metabolism.
The Europe Patent No. 0 551 626 Al discloses that with pH adjustment and addition of carbomer, said poloxamer with increased gelation temperature and viscosity is applied to skin, eye, rectum and urinary tract. Nevertheless, this invention has proven insufficient in its application to the suppository composition since it does not consider the
bioadhesive force and dissolution.
DISCLOSURE OF THE INVENTION
In order to overcome the aforementioned shortcomings, therefore, the inventor et al. have endeavored to develop a suppository composition of the drug which has gastro-intestinal disturbances or undergoes the decomposition by gastric acid.
An object of this invention is to provide a suppository composition of the drug which has gastro-intestinal disturbances or undergoes the decomposition by gastric acid, being characterized in that;
- Any disgusting feeling or discomforts does not occur, when a drug is administered;
- Administration is easy and after administration a composition is not leaked out from the anus or does not climb upto the end of the colon, thus ensuring absoφtion of the drug without gastro-intestinal disturbances or the decomposition by gastric acid.
The suppository composition of this invention comprises 0.1 — 10 weight part of a drug which has gastro-intestinal disturbances or undergoes the decomposition by gastric acid, 25 ~ 40 weight part of poloxamer and 0.1 — 1 weight part of hydrophilic natural polymers to the total blending ratio.
The drug, contained in the composition of this invention, which has gastro-intestinal disturbances, may be selected from the following materials: aspirin, acetaminophen, ketoprofen, indomethacin, naproxen, Fe compound, ketoconazole, itraconazole, econazole, cepha-antibiotics and etc., and the drug which undergoes the decomposition by gastric acid, may be selected from the following materials: propoxyphene, meperidine, methadone, penthazoic acid, dexamethazone, p-aminobenzoic acid, sulfonamides, p-aminohippuric acid, estrogens, omeprazole, pancreatine, seratiopeptidase, 1-dopa, a -methyldopa, hydrocortisone, cortisone,
aldosterone, progesteron, insulin and etc.. In case of the amount of this drug, 0.1 — 10 weight part is contained to the total suppository composition; If less than 0.1 weight part is contained, relatively enlarged volume of said composition at single dose makes it difficult to perform the rectal administration but in case of exceeding 10 weight part, the drug itself reduces the gel strength and bioadhesive force so that the adjustment of that properties become difficult.
From the suppository composition of this invention, one or more poloxamers may be selected from the following, i.e., solid-phase type (F- 127, F-l 08, F-98, F-88, F-68 and etc.), liquid-phase type (L-44, L-62, L- 64 and etc.) and paste type (P-85, P-81, P-123 and etc.). It is preferred to contain 25 — 40 weight part of poloxamer to the suppository composition; if less than 25 weight part is contained, the gel strength and bioadhesive force are weak and in case of exceeding 40 weight part, higher degree of viscosity makes it difficult to manufacture the desired product.
These poloxamers adjust the gelation temperature of the suppository composition to 30 — 36 °C ; thus, said poloxamers are in liquid phase at room temperature and in gel state within the body.
The hydrophilic natural polymers contained in the suppository composition of this invention may be used by selecting chitosan and sodium alginate independently or in a mixing form.
About 0.1 — 1 weight part of hydrophilic natural polymers is contained to the suppository composition; if less than 0.1 weight part is contained, the gel strength and bioadhesive force cannot be adjusted and sustained drug release is unavailable. Meantime, in case of exceeding 1 weight part, higher degree of viscosity makes it difficult to manufacture the desired product.
Since these hydrophilic natural polymers have hydrophilic groups such as amine group (NH.) or hydroxyl group (OH) at the end of the molecular structure which may be reacted with hydroxyl group (OH) of
poloxamer by hydrogen bond, more strong three-dimensional net¬ working structure of poloxamer may be formed. In addition to that, these polymers can form the strong hydrogen bond with oligosaccharide groups of rectal mucosa. Therefore, very small amount of those can play a role to reinforce the gel strength and bioadhesive force. Further these hydrophilic natural polymers release the drug slowly by their matrix formation at a constant concentration.
In addition to the drugs which have gastro-intestinal disturbances or undergo the decomposition by gastric acid, poloxamer and hydrophilic natural polymers, the suppository composition of this invention may also include the following additives which may be commonly applied to the conventional dosage form of rectal administration: preservatives (e.g., sodium benzoate, potassium sorbate, paraben derivatives and etc.), pH modulator (e.g., hydrochloric acid, citric acid, sodium hydroxide and etc.), stabilizers (e.g., methionine, etc.) and etc..
The suppository composition according to this invention may be prepared by dissolving these compositions in an appropriate amount of water.
The suppository composition of this invention is characterized in that;
- has the gelation temperature of 30 to 36 °C , and is a liquid form at room temperature, and readily becomes a gel at body temperature after rectal administration;
- has the remarkable gel strength, and is not leaked out the anus; - has the remarkable bioadhesive force, and doesn't climb upto the end of the colon, therefore ensures absoφtion of the drug without gastro- intestinal disturbances or the decomposition by gastric acid. Therefore, the suppository composition of this invention has neither gastro-intestinal disturbance nor the decomposition by gastric acid. With simple manufacturing process, the suppository composition may be easily manufactured with cost-saving effects.
BRIEF DESCRIPTION OF THE DRAWINGS
Fig. 1 is a graph showing the gelation temperature, when polymers are added.
Fig. 2 is a graph showing the gel strength, when polymers are added.
Fig. 3 is a graph showing the bioadhesive force, when polymers are added.
Fig. 4 is a graph showing the dissolution-controlling capacity, when polymers are added. Fig. 5 is a graph showing the results of dissolution tests related to the suppository composition of Example 1 —4.
Fig. 6 shows a microscopic picture of rectal mucosa before rectal administration (A) and a microscopic picture of rectal mucosa 4 hours after rectal administration (B). Fig. 7 is a graph showing plasma concentrations of acetaminophen of the conventional suppository composition and the suppository composition of Example 1.
BEST MODE FOR CARRYING OUT THE INVENTION This invention is explained in more detail by the following examples, but the claims are not limited to these examples.
EXAMPLE 1-4
The blending ratio involving the suppository composition according to Example 1-4 is shown in the following table 1. In the blending ratio as shown hereunder, poloxamer and hydrophilic natural polymers were dissolved in water and then, drugs and other components were successively added to the mixture for dissolving completely. Then, water was added to be a total of lOOg in the weight of this mixture and the suppository composition was finally prepared.
Table 1. Blending ratio for the suppository composition according to Example 1-4 composition Example 1 Example 2 Example 3 Example 4
F-127 15 15 15
F-l 08 13 poloxamer
F-88 14 15
F-68 19 18 hydrophilic sodium
0.1 03 natural alginate polymer chitosan 1.0 02 acetaminophen 2.5 insulin 0.09 drug omeprazole 1.0 seratio¬
0.5 peptidase methyl parahydroxy 0.06 0.06 benzoate propyl parahydroxy 0.03 0.03 benzoate additives sodium
0.05 0.1 benzoate citric acid 0.01 sodium
3.0 salicylate sodium
0.2 hydroxide water appropriate appropriate appropriate appropriate total (g) 100.0 100.0 100.0 100.0
COMPARATIVE EXAMPLE 1-4
In the same manner as described in the above compositions of Example 1-4, each composition without addition of hydrophilic natural polymers was prepared.
EXPERIMENTAL EXAMPLE 1 : Selection of polymers adaptable Jo a suppository composition
For the selection of some polymers adaptable to suppository composition of propranolol, each of the following materials by 1 weight part such as polyvinylpyrrolidone (PVP), hydroxypropylmethylcellulose (HPMC), hydroxypropylcellulose (HPC), sodium CMC, carbopol, polycarbophil, sodium alginate and chitosan was added to the mixing solution of poloxamer [F-127/F-68(15/15 weight part)], thus manufacturing the suppository compositions. The gelation temperature, gel strength and bioadhesive force related to each composition were measured. Further 2 weight part of each acetaminophen were added to the suppository composition, so prepared, so as to measure the dissolution rate of acetaminophen.
The testing criteria on the gelation temperature, gel strength, bioadhesive force and dissolution rate were as follows:
Gelation temperature: lOg of sample of the suppository composition was charged to a 20ml container, together with magnetic bar and installed to water bath at 4°C . With a digital thermometer inserted into the sample so as not to contact with the magnetic bar, the sample was stirred at a constant rate and while increasing its temperature at a rate of 1 °C/min, the gelation temperature was determined when the magnetic bar was completely stopped.
Gel strength: 50g of the suppository composition was charged to a lOOml-mass cylinder and equilibrated in water bath at 36.5 °C for 30 mins. With a gel strength device placed on a mass cylinder, the gel strength was determined by time (second) when the device went down to
5cm.
Bioadhesive force: Two sections of tissue cut from the rectal mucosa of rabbit were attached to two vials of a bioadhesive force device and between them, 0.05g of the suppository composition was added. Then, with counteφoises piled up successively, the counteφoise weight when said vials fall was calculated as a force extended per unit area.
Dissolution rate: lg of the suppository composition was charged to a semi-permeable membrane and with both sides fastened with threads, the dissolution test was performed in phosphate buffer solution of pH 6.8 at 100 φm using the paddle method. The small amount of medium was sampled at one hour intervals for analysis thereof.
These results are shown in the following table 1 and Fig. 1 -4. Fig. 1 is a graph showing the effect of the kinds of polymers on the gelation temperature. The gelation temperature of suppository composition was somewhat affected by the polymers irrespective of their kinds.
Fig. 2 is a graph showing the effect of the kinds of polymers on the gel strength and Fig. 3 is a graph showing the effect of the kinds of polymers on the bioadhesive force. Compared with the suppository composition containing polyvinylpyrrolidone, hydroxypropylmethylcellulose, hydroxypropyl- cellulose, carbopol or polycarbophil, the sodium alginate- or chitosan- containing suppository composition showed remarkably high gel strength and bioadhesive force. Fig. 4 a graph comparing the dissolution rate of acetaminophen r^m the suppository composition containing a certain scope of 0.2 ~ 0.8% concentration of sodium alginate and polycarbophil, respectively as hydrophilic polymers. While the suppository composition containing 0.2% sodium alginate showed higher dissolution rate than the polycarbophil-containing composition in same concentration, the composition containing 0.8% sodium alginate showed lower dissolution
rate than the polycarbophil-containing composition in same concentration. This revealed that the composition containing a certain scope of 0.2 — 0.8% of sodium alginate as polymers had a wider range of acetaminophen dissolution than polycarbophil-containing composition, thus showing superior dissolution-controlling capacity of the former as a hydrophilic polymer.
In the same manner as described in the above, some tests ascertained that carbopol-containing composition has similar dissolution range of polycarbophil-containing composition and chitosan-containing composition has similar dissolution range of sodium alginate-containing composition.
Since it was judged that sodium alginate and chitosan is superior to other polymers in terms of the gel strength, bioadhesive force and dissolution-controlling capacity. Therefore, the inventor et al. have selected sodium alginate and chitosan as polymers adoptable to the suppository composition of this invention.
EXPERIMENTAL EXAMPLE 2 : Measurement of gelation temperature, gel strength, leakage of the composition from the anus The gelation temperature, gel strength and bioadhesive force of
Comparative example 1-4 and Example 1-4 were measured in a same method as described in Experimental example 1. The animal experiments (assessment on leakage of the composition from the anus) were performed as follows: - lg of the suppository composition was inserted into the anus of rabbits in 5 cm depth using a stomach sonde needle for rat and with rabbits placed at 45° slope obliquely, observations for 30 mins were made and the judgment was acceptable, when the drug suppository composition was not leaked out from the anus. Its results were shown in the following table 2.
Table 2. Measurement of gelation temperature, gel strength, leakage of the composition from the anus and bioadhesive force related to compositions of Comparative example 1-4 and of Example 1-4
The above results showed that the suppository composition of Example 1-4 had lower gelation temperature, better gel strength/bioadhesive force and less leakage of the composition from the anus, than the composition of Comparative example 1-4 without hydrophilic natural polymers
EXPERIMENTAL EXAMPLE 3: Dissolution test
Each dissolution rate related to 5g of the suppository composition of Example 1 and 2g of the suppository composition of Example 2-4 was measured in a same manner as described in Experimental example 1.
The experimental results were shown in Fig. 5 and the suppository composition of Example 1-4 has proven sufficient as a preparation.
EXPERIMENTAL EXAMPLE 4: Damage test of mucosal membrane
The suppository composition of Example 1 was inserted into the anus of rat in 5cm depth using a stomach sonde needle for rat. After 4 hrs, the rectum was harvested, cut by a knife and cleansed with physiological saline solution. The rectum was fixed with formaldehyde solution neutralized with 10% carbonate, followed by paraffin and stained with hematoxylin-eosin for microscopical observation.
As revealed in following Fig. 6, rectal mucosa 4 hrs after rectal administration have no damage compared with rectal mucosa before rectal administration.
EXPERIMENTAL EXAMPLE 5: Location of composition after rectal administration
After rectal administration of the suppository composition of Example 1, comparative suppository composition [F-127/F- 68/acetaminophen (15/15/2 weight part)] and conventional suppository composition [acetaminophen/PEG 4000 (98/2 weight part)], each location was measured as follows:
Each suppository composition(0.2g) containing 0.1% Blue No. 1 Lake coloring agent was inserted into the anus of rat in 5cm depth using a stomach sonde needle for rat. The rectums of rats were harvested at intervals of 5 min, 2 hrs and 4 hrs so as to ascertain the location of the suppository composition. Its results were shown in the following table 3.
Table 3. Location of each composition after rectal administration experimental group 5 min 2 hrs 4 hrs conventional suppository composition 4-5 cm 4-5 cm 7-8 cm comparative suppository composition 4-5 cm 7-8 cm 7-8 cm
Example 1 4-5 cm 4-5 cm 4-5 cm
The suppository composition of Example 1 was found at the place
4 — 5cm away from the anus even after 4 hrs, thus reflecting that said composition did not climb upto the large intestine, while the comparative suppository composition and conventional suppository composition were found at the place 7 — 8cm away from the anus at the intervals of 2 hrs and 4 hrs, respectively, thus showing that said composition did not climb upto the large intestine.
EXPERIMENTAL EXAMPLE 6: Pharmacokinetics in_ suppository composition Male rabbits, fasted for 24-36 hours, were used as experimental animals. In order to investigate the pharmacokinetics, the experimental animals were divided into the following 2 groups with each group containing 6 rabbits: i) rectal administration group of conventional suppository composition, ii) rectal administration group of the suppository composition of Example 1.
Rats were anesthetized with urethane and fixed them on a fixing stand. In case of the group treated with the suppository composition of Example 1, 1.5 g/kg of the suppository composition containing 37.5 mg/kg of acetaminophen was inserted into the anus of rabbits at about 5cm in depth using rat sonde for oral administration; in case of the group treated with the conventional suppository composition of acetaminophen, 0.4 g/kg of the suppository composition containing 37.5 mg/kg of acetaminophen was cutted and inserted into the anus of rabbits at about 5cm in depth. In order to prevent the release of each suppository composition from the anus, a strong adhesive after administration was used for blocking the anus. 0.5ml of blood sample from the right femoral artery was collected at certain intervals, centrifuged at 3000 φm for 30 mins and harvested 0.2ml of plasma. 0.2ml of internal standard- acetonitrile (200mcg/ml) was added to the plasma and centrifuged at 3000 φm for 10 mins to precipitate protein. The resulting solution was analyzed by HPLC. Its results were shown in table 4 and Fig. 7.
Table 4. AUC, MRT, Tmax, Cmax, Kei and Un on suppository composition
* PO.05
When compared with the conventional suppository composition of acetaminophen, the suppository composition of Example 1 shows that a) the bioavailability is same, b) the mean retention time is longer, and c) peak plasma concentration is lower.
EXPERIMENTAL EXAMPLE 7: Stability test on the suppository composition
The suppository composition of Example 1 were stored at different temperatures of 4°C , room temperature (25 °C), 37°C and 45 °C for 6 months and at the intervals of 2 months, their appearances were observed by the naked eye. Then, their contents were quantified by UV.
As revealed in the following table 5, there was no significant change.
Table 5. Stability test on suppository composition
4°C 25 °C 37 t 45 °C time appea content, appea content, appear content, appear content, (months) ranee mg/5g ranee mg/5g ance mg/5g ance mg/5g (%) (%) (%) (%)
126.0 126.0 126.0 126.0
0 — — — — (100.0) (100.0) (100.0) (100.0)
125.6 126.1 124.2 125.2
1 — — — — (99.7) (100.1) (98.6) (99.4)
124.4 123.9 125.0 123.9
2 — — — — (98.7) (98.3) (99.2) (98.3)
127.6 126.5 125.2 124.0
4 — — — — (101.3) (100.4) (99.4) (98.4)
126.4 123.0 122.5 122.5
6 — — — — (100.3) (97.6) (97.2) (97.2)
( - : no change)
Claims
1. Suppository composition comprising 0.1-10 weight part of a drug which has gastro-intestinal disturbances or undergoes the decomposition by gastric acid, 25-40 weight part of poloxamer and 0.1-1 weight part of hydrophilic natural polymers.
2. Suppository composition according to claim 1 wherein a drug which has gastro-intestinal disturbances is selected from aspirin, acetaminophen, ketoprofen, indomethacin, naproxen, Fe compound, ketoconazole, itraconazole, econazole, and cepha-antibiotics.
3. Suppository composition according to claim 1 wherein a drug which undergoes the decomposition by gastric acid is selected from propoxyphene, meperidine, methadone, penthazoic acid, dexamethazone, p-aminobenzoic acid, sulfonamides, p-aminohippuric acid, estrogens, omeprazole, pancreatine, seratiopeptidase, 1-dopa, a -methyldopa, hydrocortisone, cortisone, aldosterone, progesteron, and insulin.
4. Suppository composition according to claim 1 wherein one or more poloxamers is/are selected from solid type, liquid type and paste type.
5. Suppository composition for rectal administration according to claim 1 wherein hydrophilic natural polymers are used from chitosan and sodium alginate independently or in a mixing form.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1996/7637 | 1996-03-21 | ||
| KR19960007637 | 1996-03-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1997034580A1 true WO1997034580A1 (en) | 1997-09-25 |
Family
ID=19453575
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/KR1997/000042 WO1997034580A1 (en) | 1996-03-21 | 1997-03-20 | Suppository composition of the drug which has gastro-intestinal disturbances or undergoes the decomposition by gastric acid |
Country Status (2)
| Country | Link |
|---|---|
| KR (1) | KR970064597A (en) |
| WO (1) | WO1997034580A1 (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6488954B1 (en) | 1999-02-24 | 2002-12-03 | Dong Wha Pharm. Ind. Co., Ltd. | Liquid suppository composition of diclofenac sodium |
| WO2003092734A1 (en) * | 2002-04-30 | 2003-11-13 | Kimberly-Clark Worldwide, Inc. | Temperature responsive delivery systems |
| WO2006024138A1 (en) * | 2004-08-30 | 2006-03-09 | Taro Pharmaceutical Industries Ltd. | A thermoreversible pharmaceutical formulation for anti-microbial agents comprising poloxamer polymers and hydroxy fatty acid ester of polyethylene glycol |
| WO2011072861A1 (en) | 2009-12-15 | 2011-06-23 | Bene-Arzneimittel Gmbh | Suppository comprising pantoprazole |
| WO2011129627A2 (en) * | 2010-04-14 | 2011-10-20 | Industry-University Cooperation Foundation Hanyang University | Docetaxel-loaded thermosensitive liquid suppository composition for rectal administration |
| WO2012171540A1 (en) | 2011-06-15 | 2012-12-20 | Bene-Arzneimittel Gmbh | Suppository comprising pantoprazole comprised in pellets with a cellulose core |
| WO2017021446A1 (en) * | 2015-08-05 | 2017-02-09 | Dr. Armah-Biomedica Gmbh & Co. Kg | Suppository based on a fat mass that is not sensitive to heat |
| WO2018087298A1 (en) * | 2016-11-14 | 2018-05-17 | University Of Copenhagen | Rectal insulin for treatment of inflammatory bowel diseases |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0103995A2 (en) * | 1982-08-24 | 1984-03-28 | Cilag Ag | Medicated suppository |
| US4946870A (en) * | 1986-06-06 | 1990-08-07 | Union Carbide Chemicals And Plastics Company Inc. | Delivery systems for pharmaceutical or therapeutic actives |
| EP0551626A1 (en) * | 1991-12-19 | 1993-07-21 | LEK, tovarna farmacevtskih in kemicnih izdelkov, d.d. | Thermoreversible gel as a liquid pharmaceutical carrier for a galenic formulation |
| WO1994003157A1 (en) * | 1992-07-28 | 1994-02-17 | Poli Industria Chimica S.P.A. | Pharmaceutical compositions for transmucosal delivery of peptides |
| WO1994003186A1 (en) * | 1992-07-31 | 1994-02-17 | Laboratoires Jean-Paul Martin | Vaginal mucoadhesive gel, medicament containing it and its method of preparation |
| US5292516A (en) * | 1990-05-01 | 1994-03-08 | Mediventures, Inc. | Body cavity drug delivery with thermoreversible gels containing polyoxyalkylene copolymers |
| US5346703A (en) * | 1990-08-07 | 1994-09-13 | Mediventures, Inc. | Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels |
-
1997
- 1997-03-20 KR KR1019970009499A patent/KR970064597A/en not_active Application Discontinuation
- 1997-03-20 WO PCT/KR1997/000042 patent/WO1997034580A1/en active Application Filing
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0103995A2 (en) * | 1982-08-24 | 1984-03-28 | Cilag Ag | Medicated suppository |
| US4946870A (en) * | 1986-06-06 | 1990-08-07 | Union Carbide Chemicals And Plastics Company Inc. | Delivery systems for pharmaceutical or therapeutic actives |
| US5292516A (en) * | 1990-05-01 | 1994-03-08 | Mediventures, Inc. | Body cavity drug delivery with thermoreversible gels containing polyoxyalkylene copolymers |
| US5346703A (en) * | 1990-08-07 | 1994-09-13 | Mediventures, Inc. | Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels |
| EP0551626A1 (en) * | 1991-12-19 | 1993-07-21 | LEK, tovarna farmacevtskih in kemicnih izdelkov, d.d. | Thermoreversible gel as a liquid pharmaceutical carrier for a galenic formulation |
| WO1994003157A1 (en) * | 1992-07-28 | 1994-02-17 | Poli Industria Chimica S.P.A. | Pharmaceutical compositions for transmucosal delivery of peptides |
| WO1994003186A1 (en) * | 1992-07-31 | 1994-02-17 | Laboratoires Jean-Paul Martin | Vaginal mucoadhesive gel, medicament containing it and its method of preparation |
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6488954B1 (en) | 1999-02-24 | 2002-12-03 | Dong Wha Pharm. Ind. Co., Ltd. | Liquid suppository composition of diclofenac sodium |
| KR101066763B1 (en) * | 2002-04-30 | 2011-09-21 | 킴벌리-클라크 월드와이드, 인크. | Temperature Responsive Delivery Systems |
| CN100430093C (en) * | 2002-04-30 | 2008-11-05 | 金伯利-克拉克环球有限公司 | Temperature responsive delivery systems |
| WO2003092734A1 (en) * | 2002-04-30 | 2003-11-13 | Kimberly-Clark Worldwide, Inc. | Temperature responsive delivery systems |
| US8349363B2 (en) | 2002-04-30 | 2013-01-08 | Kimberly-Clark Worldwide, Inc. | Temperature responsive delivery systems |
| WO2006024138A1 (en) * | 2004-08-30 | 2006-03-09 | Taro Pharmaceutical Industries Ltd. | A thermoreversible pharmaceutical formulation for anti-microbial agents comprising poloxamer polymers and hydroxy fatty acid ester of polyethylene glycol |
| WO2011072861A1 (en) | 2009-12-15 | 2011-06-23 | Bene-Arzneimittel Gmbh | Suppository comprising pantoprazole |
| EP2338477A1 (en) | 2009-12-15 | 2011-06-29 | bene-Arzneimittel GmbH | Suppository comprising pantoprazole |
| WO2011129627A2 (en) * | 2010-04-14 | 2011-10-20 | Industry-University Cooperation Foundation Hanyang University | Docetaxel-loaded thermosensitive liquid suppository composition for rectal administration |
| WO2011129627A3 (en) * | 2010-04-14 | 2012-02-02 | Industry-University Cooperation Foundation Hanyang University | Docetaxel-loaded thermosensitive liquid suppository composition for rectal administration |
| WO2012171540A1 (en) | 2011-06-15 | 2012-12-20 | Bene-Arzneimittel Gmbh | Suppository comprising pantoprazole comprised in pellets with a cellulose core |
| WO2017021446A1 (en) * | 2015-08-05 | 2017-02-09 | Dr. Armah-Biomedica Gmbh & Co. Kg | Suppository based on a fat mass that is not sensitive to heat |
| WO2018087298A1 (en) * | 2016-11-14 | 2018-05-17 | University Of Copenhagen | Rectal insulin for treatment of inflammatory bowel diseases |
| US11400137B2 (en) | 2016-11-14 | 2022-08-02 | University Of Copenhagen | Rectal insulin for treatment of inflammatory bowel diseases |
Also Published As
| Publication number | Publication date |
|---|---|
| KR970064597A (en) | 1997-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5631023A (en) | Method for making freeze dried drug dosage forms | |
| ES2301537T3 (en) | TABLETS AND FORMULATION OF GUAIFENESINE OF SUSTAINED LIBERATION. | |
| ES2206592T3 (en) | CONTROLLED LIBERATION MATRIX FOR PHARMACOS. | |
| Shaha et al. | An overview of a gastro-retentive floating drug delivery system | |
| JP3787071B2 (en) | Diclofenac sodium liquid suppository composition | |
| US20220280645A1 (en) | Pharmaceutical Eutectic Salt Formation | |
| CN111093653A (en) | Deuterated domperidone composition, method and preparation | |
| NZ581740A (en) | Gastroretentive system comprising an alginate body | |
| CN114727948A (en) | Extended release dosage forms of a TYK2 inhibitor | |
| CA2121038C (en) | Oral preparation for release in lower digestive tracts | |
| US20150031632A1 (en) | Orally Disintegrating Compositions of Linaclotide | |
| CN104869983A (en) | Transmucosal delivery of glatiramer acetate | |
| CA3013530A1 (en) | High bioavailability oromucosal pharmaceutical preparations based on cyclodextrin and sucralose | |
| WO1997034580A1 (en) | Suppository composition of the drug which has gastro-intestinal disturbances or undergoes the decomposition by gastric acid | |
| Ahmed et al. | Bioavailability of riboflavin from a gastric retention formulation | |
| EP1416914A1 (en) | Expandable gastric retention device | |
| US20130012454A1 (en) | Orally Disintegrating Compositions of Linaclotide | |
| JP2511577B2 (en) | Sustained-release preparation consisting of propylene glycol alginate | |
| WO2016084099A1 (en) | Soft gelatin capsule composition of anti-tussive agents | |
| Budhrani et al. | Mucoadhesive buccal drug delivery system: a review | |
| EP0913159B1 (en) | Drug delivery system using galactoxyloglucan | |
| BRPI0715756A2 (en) | pharmaceutical composition, use thereof and medicament | |
| WO1997030693A1 (en) | Suppository composition of the drug which undergo the hepatic first-pass effect | |
| JP2932086B2 (en) | New hard capsule filled with sodium picosulfate liquid | |
| CN112587651B (en) | Oral pharmaceutical composition of Bremelanotide and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA CN JP US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 97533370 Format of ref document f/p: F |
|
| NENP | Non-entry into the national phase |
Ref country code: CA |
|
| 122 | Ep: pct application non-entry in european phase |